Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13132670 | 0.91 | AADAT (0.44) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL1061828 | 0.90 | TMEM97 (0.48) | AADATPREPTMEM97SIGMAR1ABHD6 | |
| SCHEMBL12600595 | 0.90 | TMEM97 (0.48) | AADATPREPTMEM97SIGMAR1ABHD6 | |
| SCHEMBL755564 | 0.88 | AADAT (0.44) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL12565619 | 0.86 | AADAT (0.48) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL12159755 | 0.86 | AADAT (0.43) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL14886226 | 0.84 | DGAT1 (0.42) | AADATPREPTMEM97SIGMAR1ACE2 | |
| SCHEMBL27855003 | 0.83 | HCRTR1 (0.39) | — | |
| SCHEMBL3781488 | 0.83 | HCRTR1 (0.39) | — | |
| SCHEMBL18020343 | 0.83 | GPBAR1 (0.38) | PREPABHD6DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156818-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2012087976-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AADAT 2303/4885PREP 440/4885TMEM97 3246/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | AADAT 2969/4885PREP 2563/4885TMEM97 994/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | AADAT 2930/4885PREP 519/4885TMEM97 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.